Stock DNA
Pharmaceuticals & Biotechnology
JPY 180,635 Million (Small Cap)
12.00
NA
0.03%
-0.35
9.53%
1.23
Revenue and Profits:
Net Sales:
18,867 Million
(Quarterly Results - Jun 2025)
Net Profit:
271 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.31%
0%
0.31%
6 Months
1.69%
0%
1.69%
1 Year
-9.82%
0%
-9.82%
2 Years
19.46%
0%
19.46%
3 Years
0.39%
0%
0.39%
4 Years
-5.44%
0%
-5.44%
5 Years
-1.39%
0%
-1.39%
Kaken Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.05%
EBIT Growth (5y)
-4.77%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.54
Tax Ratio
28.25%
Dividend Payout Ratio
52.00%
Pledged Shares
0
Institutional Holding
0.10%
ROCE (avg)
20.37%
ROE (avg)
7.98%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.14
EV to EBIT
5.17
EV to EBITDA
4.60
EV to Capital Employed
1.24
EV to Sales
1.14
PEG Ratio
0.15
Dividend Yield
0.03%
ROCE (Latest)
24.03%
ROE (Latest)
9.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot : Jun 2024
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.1%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
18,867.00
18,254.00
3.36%
Operating Profit (PBDIT) excl Other Income
650.00
3,408.00
-80.93%
Interest
10.00
5.00
100.00%
Exceptional Items
1.00
-605.00
100.17%
Consolidate Net Profit
271.00
1,754.00
-84.55%
Operating Profit Margin (Excl OI)
0.70%
150.70%
-15.00%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 3.36% vs 0.57% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -84.55% vs -30.12% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
94,035.00
72,044.00
30.52%
Operating Profit (PBDIT) excl Other Income
23,590.00
12,267.00
92.30%
Interest
28.00
17.00
64.71%
Exceptional Items
-2,025.00
-19.00
-10,557.89%
Consolidate Net Profit
13,945.00
8,025.00
73.77%
Operating Profit Margin (Excl OI)
223.70%
132.10%
9.16%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 30.52% vs -1.29% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 73.77% vs 47.52% in Mar 2024
About Kaken Pharmaceutical Co., Ltd. 
Kaken Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






